A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Hummingbird Bioscience
Novartis
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Fate Therapeutics
Alterome Therapeutics, Inc.
Verastem, Inc.
Novartis
Revolution Medicines, Inc.
Pfizer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
AstraZeneca
Incyte Corporation
Eli Lilly and Company
Pfizer
Pfizer
Tizona Therapeutics, Inc
Genentech, Inc.
Revolution Medicines, Inc.
Jacobio Pharmaceuticals Co., Ltd.
PAQ Therapeutics, Inc.
Eli Lilly and Company
Bristol-Myers Squibb
Bristol-Myers Squibb
Servier
Genentech, Inc.
Eli Lilly and Company
Genfleet Therapeutics (Shanghai) Inc.
Bristol-Myers Squibb
InventisBio Co., Ltd
Innovent Biologics (Suzhou) Co. Ltd.
Pfizer
GlaxoSmithKline
Fate Therapeutics
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany
Eli Lilly and Company
Fate Therapeutics
NKMAX Co., Ltd.
NKGen Biotech, Inc.
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany
HiberCell, Inc.
Merrimack Pharmaceuticals
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company